logo
Twitter
Discord
Email
logo
Semler Scientific, Inc.

Semler Scientific, Inc.

NASDAQ•SMLR
CEO: Dr. Douglas Murphy-Chutorian M.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2014-02-21
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
Contact Information
2340-2348 Walsh Avenue, Suite 2344, Santa Clara, CA, 95051, United States
877-774-4211
www.semlerscientific.com
Market Cap
$253.19M
P/E (TTM)
5.1
32.2
Dividend Yield
--
52W High
$70.61
52W Low
$15.90
52W Range
1%
Rank40Top 31.7%
4.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$7.49M-44.56%
4-Quarter Trend

EPS

$1.14+42.50%
4-Quarter Trend

FCF

-$32.94M+1538.61%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Income Jumps Net income reached $16.9M for three months ended Sep 30, 2025, up $11.3M from $5.6M in prior period.
Bitcoin Asset Concentration Total assets grew to $596.7M, dominated by $539.8M in Bitcoin holdings, excluding $35.9M collateral.
Healthcare Revenue Plummets Quarterly revenues decreased 45% to $7.5M due to CMS reimbursement changes and customer testing cessation.
Financing Fuels Bitcoin Generated $320.5M in financing cash, primarily funding Bitcoin purchases and the DOJ settlement payment.

Risk Factors

Customer Testing Halts Two large customers ceased QuantaFlo use; Q4 2025 revenues anticipated at least 60% lower than Q3 2025.
Bitcoin Volatility Impact Fair value changes in Bitcoin drove $28.5M gain in three months, creating significant earnings volatility.
DOJ Settlement Expense Recorded $29.8M DOJ settlement expense in nine months, now subject to ongoing corporate integrity agreement.
Merger Uncertainty Risks Failure to complete the Strive merger or delays could negatively affect stock price and future business results.

Outlook

Strive Merger Agreement Entered merger agreement with Strive in September 2025; closing subject to stockholder approval by March 2026.
Bitcoin Treasury Expansion Intends to strategically acquire more Bitcoin, targeting 10,000 BTC by end of 2025 and 105,000 by 2027.
Healthcare Business Pivot Seeking new FDA 510(k) clearance for expanded QuantaFlo labeling; forming CardioVanta subsidiary for SaaS focus.
Debt and Equity Issuance Secured $100.0M in 2030 Senior Notes and $20.0M Coinbase loan to fund operations and settlement.

Peer Comparison

Revenue (TTM)

Owens & Minor, Inc.OMI
$6.71B
-37.1%
The Oncology Institute, Inc.TOI
$461.04M
+21.7%
Tactile Systems Technology, Inc.TCMD
$311.51M
+9.3%

Gross Margin (Latest Quarter)

Semler Scientific, Inc.SMLR
91.5%
+0.1pp
Delcath Systems, Inc.DCTH
86.3%
+5.8pp
Treace Medical Concepts, Inc.TMCI
79.1%
-1.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TCMD$662.47M45.37.3%15.4%
SRDX$614.51M-34.8-15.6%19.2%
NPCE$533.53M-25.9-116.7%66.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-15.5%
Growth Under Pressure
4Q Net Income CAGR
-16.7%
Declining Profitability
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Next earnings:May 4, 2026
|
EPS:-
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $7.49M-44.6%
    |
    EPS: $1.14+42.5%
    Meet

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 4, 2025|
    Revenue: $8.22M-43.2%
    |
    EPS: $5.71+356775.0%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 13, 2025|
    Revenue: $8.84M-44.4%
    |
    EPS: $-6.74-865.9%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 28, 2025|
    Revenue: $56.29M-17.4%
    |
    EPS: $5.66+85.0%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 5, 2024|
    Revenue: $13.51M-17.2%
    |
    EPS: $0.80-2.4%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $14.47M-22.3%
    |
    EPS: $0.00-99.8%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $15.90M-12.7%
    |
    EPS: $0.88+18.9%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 7, 2024|
    Revenue: $68.18M+20.3%
    |
    EPS: $3.06+43.7%
    Beat